Related Experiment Video
Updated: Jul 15, 2026
06:45
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease
R Pahwa1, M A Stacy, S A Factor
1University of Kansas Medical Center, Kansas City, KS 66160, USA. rpahwa@kumc.edu
Neurology
|April 4, 2007
Summary
Ropinirole 24-hour prolonged release effectively reduced "off" time in Parkinson disease (PD) patients on levodopa. This treatment improved motor and non-motor symptoms, allowing for a reduced levodopa dosage.
Area of Science:
- Neurology
- Pharmacology
Background:
- Parkinson disease (PD) often involves motor fluctuations despite levodopa therapy.
- Optimizing treatment for PD requires managing motor symptoms and improving quality of life.
Purpose of the Study:
- To assess the efficacy of ropinirole 24-hour prolonged release as an add-on therapy for levodopa-treated Parkinson disease (PD) patients experiencing motor fluctuations.
- To evaluate the impact of ropinirole 24-hour on both motor and non-motor symptoms of PD.
Main Methods:
- A 24-week, double-blind, placebo-controlled study involved 393 PD patients.
- Patients were randomized to receive either ropinirole 24-hour prolonged release or a placebo.
- The primary endpoint was the reduction in daily "off" time.
Main Results:
- Ropinirole 24-hour significantly reduced daily "off" time by 2.1 hours compared to 0.3 hours with placebo.
- Patients receiving ropinirole 24-hour experienced improvements in "on" time without dyskinesia, motor function, daily living activities, and mood.
- Common adverse events included dyskinesia and nausea; withdrawal rates were similar between groups.
Conclusions:
- Ropinirole 24-hour prolonged release is an effective and well-tolerated adjunct therapy for PD patients with motor fluctuations inadequately controlled by levodopa.
- The treatment improved motor and non-motor PD symptoms and facilitated a reduction in levodopa dosage.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:11Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
01:15REM Sleep Behavior Disorder
REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
RBD is significantly associated with...